Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9511–9519 | Cite as

High risk of development of renal cell tumor in end-stage kidney disease: the role of microenvironment

  • Anetta Nagy
  • Eva Walter
  • Dmitry Zubakov
  • Gyula Kovacs
Original Article

Abstract

End-stage renal disease (ESRD) and acquired cystic renal disease (ACRD) are associated with high risk of development of renal cell tumors (RCT) displaying unusual phenotype and genotype. The underlying molecular mechanism is not yet known. To explore the molecular microenvironment, we have established the expression profile of ESRD/ACRD kidneys. RNA extracted from normal and ESRD/ACRD kidneys and distinct types of RCT was subjected to Affymetrix HG U133 micro array analysis. A gene expression signature indicated cancer-related biological processes in the remodeling of ESRD/ACRD kidneys. Quantitative RT-PCR studies confirmed a specific gene signature including a functional group of inflammatory cytokines and also cytokeratins associated with stem cell characteristics of epithelial cells. Several of the signature genes including the SCEL were expressed in ESRD/ACRD-associated papillary RCT as well. Immunohistological analysis confirmed the expression of CXCL8 and its receptor CXCR2 as well as the expression of SCEL in hyperplastic tubular, cystic, and papillary structures and RCTs in ESRD/ACRD kidney. Our data indicates that ESRD/ACRD is a novel disease and the inflammatory microenvironment altered plasticity, and stem cell characteristics of epithelial cells may be associated with the high risk of tumor development.

Keywords

End-stage kidney disease Gene expression signature Inflammatory microenvironment Tumor development CXCL8 CXCR2 SCEL 

Notes

Acknowledgments

This work was supported by a grant of the Else-Kröner-Fresenius Stiftung, Homburg, Germany and in part by the Medical Faculty, University of Pécs, Hungary (PTE AOK KA2014/1). The authors express their appreciation to Drs. G. Staehler, B. Schulze-Brüggemann, D. Ferluga, and Mr. D. Cranston for making end-stage kidneys available and to B. Veszpremi for collecting fetal kidneys. The sciellin antibody (SC4) was kindly provided by Dr. H.P. Baden (Massachusetts General Hospital, Boston, USA).

Authors’ contributions

AN and GK designed the study and wrote the manuscript. AN and DZ evaluated the array expression study. AN and EW carried out the RT-PCR analysis. AN and GK performed the immunohistochemistry.

Compliance with ethical standards

Conflicts of interest

None

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    U.S. Renal Data System. USRDS 2013. Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2013.Google Scholar
  2. 2.
    Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991–2000). Kidney Int. 2005;67:1489–99.CrossRefPubMedGoogle Scholar
  3. 3.
    Dunnill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol. 1997;30:868–77.CrossRefGoogle Scholar
  4. 4.
    Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, et al. Cancer incidence among US Medicare ESRD patients receiving haemodialysis, 1996–2009. Am J Kidney Dis. 2015;65:763–72.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Denton MD, Magee CC, Ovuworie C, Mauiyyedi S, Pascual M, Colvin RB, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int. 2002;61:2201–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Hughson MD, Buchwald D, Fox M. Renal neoplasia and acquired cystic disease in patients receiving long-term dialysis. Arch Pathol Lab Med. 1986;110:592–601.PubMedGoogle Scholar
  8. 8.
    Ishikawa I, Kovacs G. High incidence of papillary renal cell tumors in patients on chronic haemodialysis. Histopathology. 1993;22:135–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Chudek J, Herbers J, Wilhelm M, Kenck C, Bugert P, Ritz E, et al. The genetics and morphology of renal cell tumors in end-stage renal failure may differ from those occurring in the general population. J Am Soc Nephrol. 1998;9:1045–51.PubMedGoogle Scholar
  10. 10.
    Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Pan CC, Chen YJ, Chang LC, Chang YH, Ho DM. Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma. Histopathology. 2009;55:145–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Kuntz E, Yusenko MV, Nagy A, Kovacs G. Oligoarray-CGH of renal cell tumors developed in patients with acquired cystic renal disease. Hum Pathol. 2011;41:1345–9.CrossRefGoogle Scholar
  13. 13.
    Inoue T, Matsuura K, Yoshimoto T, Nguyen LT, Tsukamoto Y, Nakada C, et al. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease. Cancer Sci. 2012;103:569–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Moskowith DW, Bonar SL, Marcus MD. Epidermal Growth factor (EGF) content of human and mouse (CPK) renal cysts. Am J Kidney Dis. 1989;14:435–6.Google Scholar
  15. 15.
    Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor c-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol. 2004;171:2166–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Cohen EP, Elliott WC. The role of ischemia in acquired cystic kidney disease. Am J Kidney Dis. 1990;15:55–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Zaidan M, Stucker F, Stengel B, Vasiliu V, Hummel A, Landais P, et al. Increased risk of solid renal tumors in lithium-treated patients. Kidney Int. 2014;86:184–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Kovacs G. High frequency of papillary renal cell tumors in end stage kidneys - is there a molecular genetic explanation? Nephrol Dial Transplant. 1995;10:593–6.PubMedGoogle Scholar
  19. 19.
    Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.CrossRefPubMedGoogle Scholar
  20. 20.
    Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226:148–57.CrossRefPubMedGoogle Scholar
  21. 21.
    Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol. 2001;2:285–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL, Singh RK. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis. 2003;20:723–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Sparman A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.CrossRefGoogle Scholar
  24. 24.
    Ning Y, Nanegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128:2038–49.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest. 2002;109:251–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Virchow R. Die krankhaften Geschwülste (Dreissig Vorlesungen, gehalten wahrend des Wintersemesters 1862–1863) Band I. Berlin, Germany: August Hirschwald.Google Scholar
  27. 27.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.CrossRefPubMedGoogle Scholar
  28. 28.
    Lindgren D, Boström AK, Nilsson K, Hansson J, Sjölund J, Möller C, et al. Isolation and characterisation of progenitor-like cells from human renal proximal tubules. Am J Pathol. 2011;178:828–37.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Commo S, Gaillard O, Bernard BA. The human hair follicle contains two distinct K19 positive compartments in the outer root sheath: a unifying hypothesis for stem cell reservoir? Differentiation. 2000;66:157–64.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang JS, Wang L, Huang H, Nelson M, Smith DI. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cells. Genes Chromosom Cancer. 2001;30:123–35.CrossRefPubMedGoogle Scholar
  31. 31.
    Giannelli G, Antonaci S. Biological and clinical relevance of laminin-5 in cancer. Clin Exp Metastasis. 2000;18:439–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Champliaud MF, Burgeson RE, Jin W, Baden HP, Olson PF. cDNA cloning and characterization of sciellin, a LIM domain protein of the keratinocyte cornified envelope. J Biol Chem. 1998;273:31547–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Champliaud MF, Baden HP, Koch M, Jin W, Burgeson RE, Viel A. Gene characterization of sciellin (SCEL) and protein localisation in vertebrate epithelial displaying barrier properties. Genomics. 2000;70:264–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. 1997;385:257–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Kobayashi A, Kwan KM, Carroll TJ, McMahon AP, Mendelsohn CL, Behringer RR. Distinct and sequential tissue specific activities of the LIM-class homeobox gene LIM1 for tubular morphogenesis during kidney development. Development. 2005;132:2809–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Champliaud MF, Viel Q, Baden HP. The expression of vitamin D-upregulated protein 1 in skin and its interaction with sciellin in cultured keratinocytes. J Investig Dermatol. 2003;121:781–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Heptinstall RH. Pathology of end stage kidney disease. Am J Med. 1968;44:656–63.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Anetta Nagy
    • 1
  • Eva Walter
    • 2
  • Dmitry Zubakov
    • 3
  • Gyula Kovacs
    • 1
    • 4
  1. 1.Medical FacultyUniversity of PecsPecsHungary
  2. 2.Department of Internal Medicine VUniversity of HeidelbergHeidelbergGermany
  3. 3.Department of Genetic IdentificationErasmus University Medical CentreRotterdamThe Netherlands
  4. 4.Medical FacultyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations